Edition of TFAM gene by CRISPR/Cas9 technology in bovine model

Vanessa Cristina de Oliveira1*, Gabriel Sassarão Alves Moreira1, Fabiana Fernandes Bressan1, Clébio Gomes Mariano Junior1, Kelly Cristine Santos Roballo1, Marine Charpentier2, Jean-Paul Concordet2, Flávio Vieira Meirelles3, Carlos Eduardo Ambroso1

1 Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering, University of São Paulo, Pirassununga, São Paulo, Brazil, 2 Laboratoire Structure et Instabilité des Génomes, Museum National d’Histoire Naturelle, INSERM U1154, CNRS UMR7196, Paris, France

* van.oliveira@usp.br, van.cristina.oliveira@hotmail.com

Abstract

The mitochondrial transcription factor A (TFAM) is a mitochondrial DNA (mtDNA) binding protein essential for the initiation of transcription and genome maintenance. Recently it was demonstrated that the primary role of TFAM is to maintain the integrity of mtDNA and that it is a key regulator of mtDNA copy number. It was also shown that TFAM plays a central role in the mtDNA stress-mediated inflammatory response. In our study, we proposed to evaluate the possibility of editing the TFAM gene by CRISPR/Cas9 technology in bovine fibroblasts, as TFAM regulates the replication specificity of mtDNA. We further attempted to maintain these cells in culture post edition in a medium supplemented with uridine and pyruvate to mimic Rho zero cells that are capable of surviving without mtDNA, because it is known that the TFAM gene is lethal in knockout mice and chicken. Moreover, we evaluated the effects of TFAM modification on mtDNA copy number. The CRISPR gRNA was designed to target exon 1 of the bovine TFAM gene and subsequently cloned. Fibroblasts were transfected with Cas9 and control plasmids. After 24 h of transfection, cells were analyzed by flow cytometry to evaluate the efficiency of transfection. The site directed-mutation frequency was assessed by T7 endonuclease assay, and cell clones were analyzed for mtDNA copy number by Sanger DNA sequencing. We achieved transfection efficiency of 51.3%. We selected 23 successfully transformed clones for further analysis, and seven of these exhibited directed mutations at the CRISPR/Cas9 targeted site. Moreover, we also found a decrease in mtDNA copy number in the gene edited clones compared to that in the controls. These TFAM gene mutant cells were viable in culture when supplemented with uridine and pyruvate. We conclude that this CRISPR/Cas9 design was efficient, resulting in seven heterozygous mutant clones and opening up the possibility to use these mutant cell lines as a model system to elucidate the role of TFAM in the maintenance of mtDNA integrity.
Introduction

The mitochondrial transcription factor A (TFAM) is a member of the High Mobility Group Box (HMGBox) subfamily structurally composed of 2 HMG domains, HMG1 and HMG2, which binds to mtDNA promoters [1–4]. The TFAM gene plays an important role in cellular physiology involved in the maintenance of mtDNA, and regulates the number of mtDNA copies. It is also essential for the initiation of transcription of mtDNA genes [5–8].

TFAM is a candidate gene for investigation of its functions in transcription and replication of mitochondrial DNA [1, 9]. TFAM is required to regulate the number of copies of mtDNA [10–11] and is essential for embryonic development in mice [12]. In bovine oocytes at different embryonic stages, the great importance of TFAM in the maintenance of the first stages of embryogenesis has been reported [13].

The possibility of modifying cellular genome sequences has recently become a reality due to various gene-editing techniques, and this has many important applications, such as investigating the role of mutations in predisposition to diseases. Recently, gene-editing tools have been based on the CRISPR/Cas9 system (Clustered Regularly Interspaced Short Palindromic Repeats). This originates as a system found in bacteria and archaea and is an adaptive defense mechanism protecting against invasion of exogenous DNA [14].

CRISPR/Cas9 uses a short gRNA containing 20 nucleotides complementary to a DNA sequence, as well as an RNA-guided Cas9 nuclease. When gRNA binds to the target site, the Cas9 protein induces breaks in the two strands of DNA. CRISPR/Cas9 has emerged as a powerful tool that has been used in various applications, including human and veterinary medicine.

Regarded as a key protein in the mtDNA maintenance, the TFAM gene was silenced in mice by Cre-loxP technique, resulting in loss of embryonic lethality and mtDNA decrease. That research also showed the importance of TFAM in the molecular process involved in maintaining mtDNA integrity, allowing future development of works regarding this gene. Hence, our study proposed to edit the TFAM gene in bovine fibroblasts by CRISPR/Cas9 technology, firstly in order to assess if it’s possible to edit it by this tool, maintain the edited cells in culture since the embryonic TFAM disruption is lethal, and in the future characterize the generated cells and discover their application potential. Among genes that regulate mitochondrial transcription and replication activity, TFAM exerts considerable interspecific variability. In this context, we intended to edit the TFAM gene precisely because of the possibility of this gene being the main specificity regulator of mtDNA replication, allowing in the future to modify the TFAM origin and eventually control and repopulate a cell with its specific mitochondria harvested in different species.

Materials and methods

Our study protocol was approved by the Research Ethics Committee (Approval No. 5828250215) of the Faculty of Animal Science and Food Engineering, University of São Paulo, Brazil.

Cell line

Bovine fibroblasts used in this study were derived from a skin biopsy; the tissue was minced into small pieces and digested with collagenase type IV (Sigma C2674) for 3h at 37˚C. The tissue was then centrifuged at 1500 rpm and the resultant pellet resuspended in Iscove’s modified Dulbecco’s medium (IMDM) (Gibco) supplemented with 10% fetal bovine serum (Hyclone) and antibiotics (5% penicillin–streptomycin; Invitrogen, Carlsbad, CA, USA).
CRISPR

Design. The sequence of the TFAM gene was obtained from the GenBank NR database (www.ncbi.nlm.nih.gov). For CRISPR targeting, exon 1 DNA sequence of the bovine TFAM gene was entered into the ‘CRISPR Direct’ site (crispr.dbcls.jp) and also to the rgenome site (rgenome.net) so as to design the gRNA (Fig 1). The design of gRNA was facilitated using these freely available, online tools. We employed these tools to identify guide sequences and to minimize identical genomic matches or mismatches to reduce the risk of off-target modifications. We designed four gRNAs for evaluation.

Cloning-Hybridization of gRNA oligonucleotides. Oligos with gRNA sequences were resuspended at a concentration of 100μM in ddH2O and 5μL each of the sense and antisense primers were added to a mix of 35μL water, 5μL NEB2 buffer and hybridized at 90˚C for 5 minutes, then cooled at room temperature for 2 hours.

Ligation reaction for annealed oligos. From the products of hybridization, 1μL was mixed with 5μL of T4 DNA ligase (Invitrogen) and 9μL of the vector mix containing linearized plasmid pMLM3636 (Addgene #43860), T4 Buffer, and water. The total volume reaction was 15μL. The mixture was incubated at 16˚C for 1 hour and then at 65˚C for 10 minutes to inactivate the enzyme.

Transformation

Bacteria (E. coli C3019, NEB 10-beta) were transformed by heat shock as follows: 2μL of ligation reaction was mixed with 7μL bacteria, incubated on ice for 30 minutes, and then transferred to a water bath at 42˚C for 30 seconds. They were added to 200μL of Luria-Bertani broth (LB) medium. The culture was then incubated at 37˚C for 1 hour and subsequently spread on LB/Amp/Agar plates. The plates were incubated at 37˚C for 16 hours until the appearance of colonies. Individual colonies were placed in 25mL of LB medium with ampicillin. These were incubated with constant agitation for 12 hours after which they were removed, subjected to DNA miniprep extraction (QIAprep Spin Miniprep Kit- cat. nos. 27104 and 27106), and followed by DNA sequencing.

Fig 1. Scheme of guide RNA and PAM sequence targeting exon 1 in the bovine TFAM gene. Note the complete sequence of Exon 1. The horizontal red underline represents the PAM sequence. The horizontal black underlined region represents the guide sequence and the cut site is the vertical black dotted line.

https://doi.org/10.1371/journal.pone.0213376.g001
Transfection of bovine fibroblasts

Bovine fibroblasts cultured to 85% confluency were separated for transfection. Test assays were run to determine the most suitable program of Amaxa Nucleofector equipment. Control cells were transfected with pCAG expression vector (a kind gift of M. Jasin, similar to Addgene #26477 but lacking ISceI cDNA). We observed that all the programs tested (A-24, T-016, U-012, U-013 e V-013) led to a high rate of transfection (Fig 2). U-012 was chosen due to its high efficiency, resulting in 98.4% cell transfection and good cell viability after re-culturing.

After determining the most convenient program, we proceeded to transfection with Cas9 (Addgene 48868), with the same plasmids and we tested 4 different gRNA. We used the Nucleofector Kit for Primary Mammalian Fibroblasts (VPI-1002). The transfection was performed with $1 \times 10^6$ cells per sample that were collected and washed twice in phosphate-buffered saline (PBS) and centrifuged. After that, cells were resuspended in 100μL Nucleofector Solution with 2 μg of Cas9 plasmid, 6 μg of gRNA plasmid and 2 ng GFP plasmid of Amaxa Transfection Kit. The cell and DNA mixture was transferred into a cuvette and electroporated with Amaxa Nucleofector 2B using the Program U-012. After transfection, the cells were cultured in DMEM medium supplemented with 20% fetal bovine serum (FBS) (Sigma), 50μg/mL uridine and 100μg/mL pyruvate for two days and then used for further analysis.

DNA was extracted to perform T7EI gel test to detect the best mutation rate between all 4 gRNA. The mutation rate was quantified by scanning of DNA bands with Image J software (NIH Image-BioLab). gRNA1 and gRNA2 had no mutation. gRNA3 had a 7.2% mutation rate and gRNA4 had a 10% mutation rate. Having chosen the most adequate protocol and gRNA (gRNA4), a new transfection was performed in the same conditions in order to generate edited cells (Fig 3). Two days after transfection, cells were analyzed using the FACSARia flow cytometer and through cellular fluorescence photography.
Cell cloning through fluorescence activated cell sorting (FACS) of transfected cells

Transfected cells with greater than 70% confluence were isolated by sorting 1 cell/well into 96-well plates using FACS Aria (BD Bioscience) equipped with FACSDiva software for analysis. These cells were cultured in 100 μL of DMEM supplemented with FBS, uridine and pyruvate. The cells were incubated at 37˚C with 5% CO₂ and relative humidity at approximately 80% for 20 days.

T7EI test for quantitating frequencies of indels (insertion or deletion) mutations and Topo Cloning

Genomic DNA was extracted from cells using Qiamp DNA microkit (Qiagen), according to the manufacturer’s protocol. To assess mutation frequencies, T7EI endonuclease assays were performed [15]. The genomic region (gRNA target site) was PCR amplified using primers (Table 1). PCR products were mixed with 2 μL NEB buffer 2.0 (New England Biolabs) and water to make a total volume of 20 μL. The mixture was denatured and annealed to form heteroduplexes. After that, we performed digestion with 0.32 μL T7EI endonuclease (10 units/μL) at 37˚C for 30 minutes. To analyze DNA digestion, the products were electrophoresed on a 2.5% agarose, 50% sucrose with proteinase K (20 ng/μL) gel. The mutation rate was quantified by scanning of DNA bands with Image J software (NIH Image-BioLab). The PCR products were sent for Sanger sequencing.

To identify the mutant alleles, the PCR products were cloned by TOPO TA Cloning Kit (Life Technologies) vector prepared according to the manufacturer’s instructions and sent for Sanger sequencing.

Determination of mtDNA copy number

The mtDNA copy number was estimated [16], samples (fibroblasts in P3) were subjected to total DNA extraction, the DNA was quantified by spectrophotometry (NanoDrop 2000,
Thermo Scientific, Waltham, MA, USA) and frozen at -80˚C. mtDNA quantification was then performed on a real-time PCR thermocycler (Applied Biosystems, 7500 Fast Real Time PCR System, Foster City, CA, USA) using a commercial assay system (SYBR Green PCR Master Mix; Life Technologies) following the manufacturer instructions. The samples were analyzed in duplicate using the endogenous beta actin gene (ACTB) as a control and primers listed in Table 2.

### Statistical analysis

The statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc. San Diego, CA). One-way Analysis of variance (ANOVA) with \( p \leq 0.01 \), followed by Tukey’s test.

### Results

#### Transfection of bovine fibroblasts

After being transfected the cells grew well in culture, showing adherence to plastic and fibroblastoid format and cells positively stained to GFP (Fig 4). We obtained a successful transfection rate of 51.3% GFP positive cells (S1 Fig).

#### Cell clone culture

The cells were cultured for a period of 20 days, analyzed, and the wells containing individual colonies were selected and then split into 6-well plates, where the cells reached confluence after 4 days in culture. We observed that the clones grew well in culture with uridine and pyruvate showing that the supplementation support the cells in vitro (Fig 5).

#### Conventional PCR analysis

PCR was performed for amplification of the target region; for all clones, a band of the expected molecular weight was obtained (see S2 Fig for details).

#### T7EI test of clones, TOPO TA Cloning and sequencing

After T7EI tests, we observed that 7 clones presented mutations. Through DNA sequencing, we were able to confirm the mutations. Close to the target region, the presence of 2 peaks was noticed, probably due to heterozygous mutations. The CRISPR mechanism cleaves 3 base pairs prior to the PAM (Protospacer adjacent motif) region and in all of our clones, we noticed a deletion in this region (Fig 6). We confirmed the heterozygous mutations through PCR products that were cloned by TOPO TA Cloning Kit (Life Technologies) vector and sent for Sanger sequencing. Several colonies from the same clone were analyzed. The sequencing results showed in all of the samples only one allele edited (Fig 7).
Determination of mtDNA copy number

Regarding the determination of the mtDNA copy number we observed a decrease in the copy number in the edited clones (heterozygous) when compared to non-edited (control) clones of bovine fibroblasts. The non-edited clones showed 2.912 copy number on average and the edited clones 1.655 mtDNA copy number (Fig 8). These results reveal that the CRISPR/Cas9 editing was efficient and even though only one allele was edited it was enough to present a significative difference ($P \leq 0.01$) in the mtDNA copy number.

Discussion

Genetic editing in cattle is an important tool for generating gene knockouts in animal models, such as in herds for pharmaceutical purposes. These genetic modifications are of extreme importance for both agricultural science and biomedical applications, rendering this particular animal model more suitable for gene therapy when compared to laboratory rodent models [5,17–19].

CRISPR/Cas9 has already been used in bovids and has demonstrated the feasibility of manipulation of the Nanog gene. This mechanism was highly efficient in both bovine embryos and pluripotent stem cells [20].

In our study, we used CRISPR/Cas9 technology to edit the TFAM gene in bovine fibroblasts. We designed a gRNA using the website crispr.dbcls.jp, following the protocol previously reported for zebrafish [21]. For transfection of bovine fibroblasts, we used AMAXA Nucleofector 2B equipment because it is a method based on a combination of solutions and electrical
parameters that directly transfers DNA to cell nuclei. This technique has been used by several authors in many primary cell types [22–24].

Many authors report the use of electroporation in bovine fibroblasts and found it to be very efficient for DNA transfection, as well as for fibroblastoid cells of other mammals [25].

Fig 5. Selected clones. Clones after 7-day growth in 6-well plates. Note adherence to plastic and high cell confluence. In A-B, cells in 96-well plates at 80% confluence; C-D confluent cells in 6-well plates.

https://doi.org/10.1371/journal.pone.0213376.g005

Fig 6. Mutation detection of TFAM gene by T7EI cleavage assay and sequence analysis. In the T7EI assay note mutations in numbers 1 to 3. It’s possible to see 2 bands in the center of the gel and the numbers 4, 5, and 6 are controls of clones 1–3. In the PCR sequencing analysis note A, B and C (nucleotides 163–165) showing the PAM region of the sequence. The cleavage site is 3bp prior to PAM (160–162). In A, note the insertion of two A residues at the site that should be GC. At nucleotide 155, there also occurred an insertion of G, normally an A. In B, note the insertion of an A substitution for G. In C the insertion of AT nucleotides involving positions 156 and 157. This site is normally GC. Also insertion of a T at the A site of nucleotide 151, and insertion of C at the G site at nucleotide 144.

https://doi.org/10.1371/journal.pone.0213376.g006
In our study, we performed GFP plasmid transfection into bovine fibroblasts. As a result of our experiments to generate DNA editing using CRISPR/Cas9, when pGFP plasmid was combined with gRNA and Cas9 expression plasmids, we observed a transfection rate of 51.8% using Amaxa running program U-012.

As the disruption of the TFAM gene is expected to be lethal, in order to maintain the post-transfected cells in culture we supplemented the culture medium with uridine and pyruvate, similar to Rho 0 cells that are capable of surviving without mtDNA when exposed to these conditions. Rho 0 cells are entirely dependent on glycolysis for their energy demands, as well as being auxotrophic for uridine because the enzyme responsible for the synthesis of this...
nucleoside (dehydrogenase dihydroorotate) is located in the inner mitochondrial membrane and requires the function of the electron transport chain for its activity [26–27].

Rho 0 cells require a medium supplemented with uridine and pyruvate as energy sources so they can proliferate and survive [26–28]. Thus, transfected cells treated with uridine and pyruvate have the ability to be maintained in vitro similar to cells that do contain mtDNA. To carry out supplementation, we followed the same protocol as used in bovine fetal fibroblasts treated with ethidium bromide to evaluate the effects on the number of mitochondrial DNA copies and their actions involving cellular metabolism. The treated and control fibroblast cultures supplemented with uridine and pyruvate were stably maintained in culture, and it was observed that such treatment did not affect cellular growth rate and that supplementation was able to support normal cell proliferation [29–30]. This is similar to our findings, in that cells remained viable post-transfection, without affecting cell growth rate.

In the CCR5 gene, gene knockout was performed in fibroblasts and in human embryonic stem cells through transfection using the AMAXA protocol, with a mutation rate of 19% in fibroblasts and 23% in H9 embryonic stem cells from humans [31].

In sheep fibroblasts, knockout was performed in the myostatin gene, and by PCR assays, a cleavage efficiency of 19.3% was identified [32].

In our findings, the initial mutation rate identified in bovine fibroblasts was 7.2% and 10%, but we found that increasing the concentration of Cas9 and gRNA could raise the rate to 40% efficiency. However, when clones from cells transfected with the highest amount of Cas9 plasmid were cultured, we noticed that they did not grow well and soon underwent apoptosis, suggesting that high concentrations of Cas9 may be toxic to cells. Higher concentrations of Cas9 result in higher mutation rates at target sites, but may possibly generate off-target modifications, which may contribute to toxicity [33].

After refining our methods we generated a mutation in fibroblasts; with the analysis of the clones we found mutations and we isolated heterozygous clones carrying one mutant and one wild-type TFAM allele. Therefore, we believe that we generated a new interesting model for further study because heterozygosity should decrease the amount of TFAM protein by 50%, possibly leading to mitochondrial dysfunctions and the generation of diseases, as overexpression (due to a high mtDNA compaction, thus hindering replication) or low expression can lead to decreased numbers of mitochondrial copies [34].

Research in mice with heterozygous TFAM mutation showed a reduction in mtDNA copy number and lethality in TFAM homozygosis [35].

The heterozygous TFAM -/+ mouse had decreased copy numbers of myocardial mtDNA and homozygous -/- mice showed depletion of mtDNA with a decrease in OXPHOS and death during embryonic development [36]. Conversely, high TFAM expression in transgenic mice increased the number of mtDNA copies, showing that this increase may improve severe symptoms of certain mitochondrial diseases [37]. It has also been reported that an unbalance in the mtDNA copy number due to TFAM alterations may be associated with many neurodegenerative and cardiac diseases, as well as cancer [38–39].

Other studies show that heterozygous TFAM make mice more prone to suffer metastasis in an intestinal cancer model [40].

Regarding the cardiac issue, recent studies have demonstrated that TFAM inhibits the NFAT4-MMP9 proteolytic pathway in TFAM transgenic mice subjected to aorticbanding-induced heart failure, reducing pathological cardiac remodeling like hypertrophy and other HF associated factors. When KO’d, the absence of TFAM induces the activation of proteases Calpain1, MMP9 and NFAT4, resulting in pathological remodeling of the heart and increased ROS production. So, when overexpressed, TFAM reduced all of these HF effects by inhibiting
the NFAT4-MMP9 cardiac remodeling cascade, postulating TFAM as a possible therapeutic approach to cardiac pathologies [38–39].

Other studies addressed the relation between Krüppel-like (KLF) transcription factors, TFAM and cancer. KLF are DNA-binding proteins that regulate gene expression and the noted research showed that they play a key role in the differentiation and development of tumors and the regulation of carcinogenesis, being capable of both promoting and suppressing tumor appearance, according to the cellular context. In this research the quantities of KLF16 were altered showing that it helps to modulate TFAM in glioma cells, hindering (or otherwise increasing) the cancerous cells proliferation rate by targeting the main mitochondrial transcription factor, thus demonstrating a new potential approach for the TFAM gene [41].

Considering the mtDNA copy number our results were consistent with the literature because our edited fibroblasts -/+ also showed the expected decrease in mtDNA when compared to unedited clones, confirming the important role of TFAM in mtDNA modulation and preservation. From our studies, the CRISPR/Cas9 design was efficient to generate clones with mutation through disruption of TFAM gene. This new cell line with heterozygosity of the TFAM gene affords a tool to confirm that TFAM has direct action involving mtDNA in bovids. For example, it can play a fundamental role in the maintenance of genetic stability, inheritance and segregation.

Supporting information
S1 Fig. Diagram of flow cytometry. Note the 51.3% of GFP positive cells.
(JPG)

S2 Fig. Conventional PCR analysis and 1.5% agarose gel electrophoresis. PCR of clones (1 to 7) showing the 361 bp amplified region.
(TIF)

Acknowledgments
We would like to thank to Center of Cell Therapy, Regional Blood Center of Ribeirão Preto-Brazil for technical assistance in the transfection of cells and G Church, K Joung and M/ Jasin labs for plasmids and Dr. We thank the PhD. Marcos Roberto Chiaratti for their collaboration and technical assistance.

Author Contributions
Conceptualization: Vanessa Cristina de Oliveira, Jean-Paul Concordet, Flávio Vieira Meirelles, Carlos Eduardo Ambrósio.

Data curation: Vanessa Cristina de Oliveira, Gabriel Sassarão Alves Moreira, Fabiana Fernandes Bressan, Jean-Paul Concordet.

Formal analysis: Vanessa Cristina de Oliveira, Gabriel Sassarão Alves Moreira, Fabiana Fernandes Bressan, Kelly Cristine Santos Roballo, Jean-Paul Concordet, Flávio Vieira Meirelles, Carlos Eduardo Ambrósio.

Investigation: Vanessa Cristina de Oliveira, Clésio Gomes Mariano Junior, Marine Charpentier, Jean-Paul Concordet, Flávio Vieira Meirelles, Carlos Eduardo Ambrósio.

Methodology: Vanessa Cristina de Oliveira, Fabiana Fernandes Bressan, Kelly Cristine Santos Roballo, Marine Charpentier, Jean-Paul Concordet, Flávio Vieira Meirelles.

Project administration: Vanessa Cristina de Oliveira, Carlos Eduardo Ambrósio.
Resources: Vanessa Cristina de Oliveira, Jean-Paul Concordet, Carlos Eduardo Ambrósio.

Software: Marine Charpentier.

Supervision: Flávio Vieira Meirelles, Carlos Eduardo Ambrósio.

Validation: Vanessa Cristina de Oliveira, Jean-Paul Concordet, Flávio Vieira Meirelles, Carlos Eduardo Ambrósio.

Visualization: Vanessa Cristina de Oliveira, Jean-Paul Concordet, Flávio Vieira Meirelles.

Writing – original draft: Vanessa Cristina de Oliveira, Fabiana Fernandes Bressan, Clésio Gomes Mariano Junior.

Writing – review & editing: Vanessa Cristina de Oliveira, Clésio Gomes Mariano Junior, Jean-Paul Concordet, Carlos Eduardo Ambrósio.

References

1. Choi YS, Kim S, Pak YK. Mitochondrial transcription factor A (mtTFA) and diabetes. Diabetes Res Clin Pract. 2001; 54 Suppl 2:S3–9. PMID: 11733104.

2. Garstka HL, Facke M, Escribano JR, Wiesner RJ. Stoichiometry of mitochondrial transcripts and regulation of gene expression by mitochondrial transcription factor A. Biochem Biophys Res Commun. 1994; 200(1):619–26. https://doi.org/10.1006/bbrc.1994.1493 PMID: 8166737.

3. Scarpulla RC. Nuclear activators and coactivators in mammalian mitochondrial biogenesis. Biochim Biophys Acta. 2002; 1576(1–2):1–14. PMID: 12031478.

4. Canugovi C, Maynard S, Bayne AC, Sykora P, Tian J, de Souza-Pinto NC, et al. The mitochondrial transcription factor A functions in mitochondrial base excision repair. DNA Repair (Amst). 2010; 9 (10):1080–9. https://doi.org/10.1016/j.dnarep.2010.07.009 PMID: 20739229; PubMed Central PMCID: PMCPMC2955416.

5. Choi W, Yum S, Lee S, Lee W, Lee J, Kim S, et al. Disruption of exogenous eGFP gene using RNA-guided endonuclease in bovine transgenic somatic cells. Zygote. 2015; 23(6):916–23. https://doi.org/10.1017/S096719941400063X PMID: 25424059.

6. Falkenberg M, Gaspari M, Rantanen A, Trifunovic A, Larsson NG, Gustafsson CM. Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet. 2002; 31(3):289–94. https://doi.org/10.1038/ng909 PMID: 12068295.

7. Hallberg BM, Larsson NG. TFAM forces mtDNA to make a U-turn. Nat Struct Mol Biol. 2011; 18 (11):1179–81. https://doi.org/10.1038/nsmb.2167 WOS:000296734200001. PMID: 22056802.

8. Kukat C, Larsson NG. mtDNA makes a U-turn for the mitochondrial nucleoid. Trends in Cell Biology. 2013; 23(9):457–63. https://doi.org/10.1016/j.tcb.2013.04.009 WOS:000324791800006. PMID: 23721879.

9. Gunther C, von Hadeln K, Muller-Thomsen T, Alberici A, Binetti G, Hock C, et al. Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neuroscience Letters. 2004; 369(3):219–23. https://doi.org/10.1016/j.neulet.2004.07.070 WOS:000224596700010. PMID: 15464268.

10. Kang I, Chu CT, Kaufman BA. The mitochondrial transcription factor TFAM in neurodegeneration: Emerging evidence and mechanisms. FEBS Lett. 2018; 592(5):793–811. https://doi.org/10.1002/1873-3468.12999 PMID: 29364506.

11. Chen X, Li S, Ke Y, Wu S, Huang T, Hu W, et al. KLF16 suppresses human glioma cell proliferation and tumourigenicity by targeting TFAM. Artificial Cells, Nanomedicine, and Biotechnology. 2018; 29:1–8. https://doi.org/10.1080/21691401.2018.1431654 PMID: 29374989.

12. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet. 2004; 13(9):935–44. https://doi.org/10.1093/hmg/ddh109 WOS:000220896600004. PMID: 15016765.

13. May-Panloup P, Vignon X, Chretien MF, Heyman Y, Tamassia M, Matthey Y, et al. Increase of mitochondrial DNA content and transcripts in early bovine embryogenesis associated with upregulation of mtTFA and NRF1 transcription factors. Reprod Biol Endocrinol. 2005; 3:65. https://doi.org/10.1186/1477-7827-3-65 PMID: 16285882; PubMed Central PMCID: PMCPMC1298334.

14. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science. 2012; 337(6096):816–21. https://doi.org/10.1126/science.1225829 WOS:000307535600036. PMID: 22745249.
15. Renaud JB, Boix C, Charpentier M, De Cian A, Cochenneaux J, Duvernois-Berthet, et al. Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases. Cell Rep, 2016; 8-14(9):2263–2272. https://doi.org/10.1016/j.celrep.2016.02.018 PMID: 26923600

16. Nicklas JA, Brooks EM, Hunter TC, Single R, Branda RF. Development of a quantitative PCR (TaqMan) assay for relative mitochondrial DNA copy number and the common mitochondrial DNA deletion in the rat. Environ Mol Mutagen 2004; 44 (4):313–320. https://doi.org/10.1002/em.20050 PMID: 15476199

17. Mittenberg R, Williams MA, Berkey CS, Cotter PF. The Length of Uncomplicated Human Gestation. Obstet Gynecol. 1990; 75(6):929–32. WOS:A1990DE77800008. PMID: 2342739

18. Pessoa LV, Bressan FF, Chiaratti MR, Pires PR, Perecin F, Smith LC, et al. Mitochondrial DNA dynamics during in vitro culture and pluripotency induction of a bovine Rho0 cell line. Genet Mol Res. 2006; 5(1):55–62. PMID: 16755497.

19. Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, et al. Reconstruction of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interferon-γ production of patients with systolic lupus erythematosus. Arthritis Rheum. 1948; 48.

20. Wang Z. Genome engineering in cattle: recent technological advancements. Chromosome Res. 2015; 23(1):17–29. https://doi.org/10.1007/s10577-014-9452-6 PMID: 25596824.

21. Kim MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989; 246(4929):500–3. PMID: 2814477.

22. Kim MP, Attardi G. Isolation of human cell lines lacking mitochondrial DNA. Methods Enzymol. 1996; 264:304–13. PMID: 8965704.

23. Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014; 24(6):1012–9. https://doi.org/10.1101/gr.171322.113 PMID: 24969461; PubMed Central PMCID: PMCPMC4032847.

24. Han H, Ma Y, Wang T, Lian T, Tian X, Hu R, et al. One-step generation of myostatin gene knockout sheep via the CRISPR/Cas9 System. Frontiers Agr Sci Eng. 2014; 1:2–5.

25. Peng R, Lin G, Li J. Potential pitfalls of CRISPR/Cas9-mediated genome editing. FEBS J. 2016; 283 (7):1218–31. https://doi.org/10.1111/febs.13586 PMID: 2635798

26. Kang D, Hamasaki N. Mitochondrial transcription factor A in the maintenance of mitochondrial DNA: overview of its multiple roles. Ann N Y Acad Sci. 2005; 1042:101–8. https://doi.org/10.1196/annals.1338.010 PMID: 15965051.

27. Larsson NG, Wang J, Wehmssn H, Oldfors A, Rustin P, Lewandoski M, et al. Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet. 1998; 18 (3): 231–36. https://doi.org/10.1038/ng0398-231 PMID: 9500544
36. Marin-Garcia J. Mitochondrial DNA repair: a novel therapeutic target for heart failure. Heart Fail Rev. 2016; 21(5):475–87. https://doi.org/10.1007/s10741-016-9543-x PMID: 26940911.

37. Nishiyama S, Shitara H, Nakada K, Ono T, Sato A, Suzuki H, et al. Over-expression of Tfam improves the mitochondrial disease phenotypes in a mouse model system. Biochem Biophys Res Commun. 2010; 401(1):26–31. https://doi.org/10.1016/j.bbrc.2010.08.143 PMID: 20816751.

38. Kunkel GH, Chaturvedi P, Theilen N, Nair R, Tyagi SC. Mechanism of TFAM mediated cardiomyocyte protection. Can J Physiol Pharmacol 2017; 96(2):173–181. https://doi.org/10.1139/cjpp-2016-0718 PMID: 28800400

39. Kunkel GH, Kunkel CJ, Ozuna H, Miralda I, Tyagi SC. TFAM overexpression reduces pathological cardiac remodeling Mol Cel Biochem. 2018. https://doi.org/10.1007/s11010-018-3459-9 PMID: 30353496

40. Woo DK, Green PD, Santos JH, D'Souza AD, Walther Z, Martin WD, et al. Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC (Min+) mice. Am J Pathol. 2012; 180 (1): 24–31. https://doi.org/10.1016/j.ajpath.2011.10.003 PMID: 22056359

41. Chen X, Li S, Ke Y, Wu S, Huang T, Hu W, et al. KLF16 suppresses human glioma cell proliferation and tumorigenicity by targeting TFAM. Artif Cells, Nanomed, and Biotechnol 2018; 29:1–8 https://doi.org/10.1080/21691401.2018.1431654 PMID: 29374989